Analysts Project Prolonged Austerity For European Device Markets
This article was originally published in The Gray Sheet
Executive SummaryEuropean industry expectations of an economic recovery in 2011 on the heels of budgetary challenges are likely to fall short and may hold significance for the U.S., Morgan Stanley analysts said during a March 18 conference call.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.